Introduction: Elevated levels of reactive oxygen species (ROS) have been
List of
42 DEGs between HT-PTC versus PTC group. Dominantly expressed tissue and ROS-related function of DEGs are indicated by check sign. Significantly enriched pathways in HT-PTC group from the GSEA analysis.
v 
List of Figures

Introduction
The clinical association between Hashimoto thyroiditis (HT; chronic lymphocytic thyroiditis) and papillary thyroid carcinoma (PTC) has been extensively studied, but the precise relationship between these two diseases is still being debated. Several analyses of surgical resection specimens have shown that PTC is frequently accompanied by HT. Interestingly, PTC with HT is associated with a lower rate of neck lymph node metastasis and has a better prognosis than PTC without thyroiditis in spite of increased incidence correlation [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In contrast, other studies conducted by fine-needle aspiration biopsy specimens and ultrasonographic findings have found no correlation between the incidences of these two diseases, with researchers insisting that HT does not increase the risk of thyroid cancer [11] [12] [13] . To date these studies have consisted only of clinical retrospective reviews. To resolve the controversial relationship between these two diseases that occur in the same organ, additional biological and/or genomic evidence is needed.
One possible biological mechanism for a connection between these two diseases is the elevated levels of reactive oxygen species (ROS), expelled from the lymphocytes during the progression of HT [14, 15] . HT is a chronic autoimmune disease accompanied by extensive infiltration of lymphocytes.
Lymphocytes produce ROS as a byproduct of cell-mediated immune processes.
Although ROS production from the lymphocytes increases in HT, we cannot safely conclude that the total amount of intra-thyroidal ROS level also rises enough to induce the development of cancer because thyroid cells normally produce huge amounts of hydrogen peroxide (H2O2), a typical form of ROS, during thyroid hormone biosynthesis. With the progression of HT, thyroid cells are destroyed by the lymphocytic invasion. Thyroid hormone production ceases and byproduct ROS production is also stopped as thyroid cell destruction proceeds [16] . In summary, ROS production from the lymphocytes was increased but ROS from normal thyroid cells was decreased. Therefore, it is difficult to estimate the changes in total intra-thyroidal ROS levels in thyroid gland with HT.
To circumvent these challenges, we took a bioinformatics approach to reveal 
Materials and Methods
TCGA data processing and making subgroups Eight results from metastatic tissue were excluded. Next, we examined all clinical records and excluded samples with lack of pathologic information.
Patients with a history of external radiation exposure were also excluded because the radiation could have degraded ROS-related systems and thus acted as a critical confounding factor in this ROS-related study. PTC without HT and PTC with HT. Although the TCGA data had already been normalized, we verified the density plot to flag outlier samples ourselves and identified two outliers that we excluded from our analysis (Fig. 2) . The final analysis included the following three groups: (1) Normal thyroid (n = 33, hereafter referred to as "Normal group", (2) PTC without HT (n = 232, "PTC group"), and (3) PTC with HT (n = 60, "HT-PTC group"). [18] .
Statistical analysis
All statistical analyses were performed in R.3.1.2 [19] , with graphs generated in the same program. (scavenging) from microenvironment [20] . We also checked gene ontology enrichment using up-regulated genes in HT-PTC or PTC group with DAVID gene ontology analyzing tool. The Gene Set Enrichment Analysis (GSEA)
program was used for pathway analysis [21] . We initially inputted all 20,531 gene expression counts from the RNA sequencing RSEM results to find which pathways were differently enriched between HT-PTC and PTC group. The
Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used to reference pathway database in GSEA program [22] . Additionally, we used our three ROS-related gene sets as another metric to determine whether these specific ROS-related gene sets were enriched or not in the HT-PTC group. In GSEA, an FDR q-value < 0.25 was considered to indicate statistically significant enrichment. Twelve genes showed significant differential expression pattern under the t-test p-value < 0.05 between HT-PTC and PTC groups. Eleven genes were upregulated in HT-PTC and one gene was up-regulated in PTC (Fig. 5) . The differential expression patterns of these 12 genes were the same as the TCGA fold change results. Gene ontology (GO) and gene set enrichment analysis Table 3 shows the significantly enriched GOs in biologic process using upregulated ROS-related DEGs as input to DAVID analysis. Total 24 GOs were significantly enriched. Twelve GOs were related to ROS metabolism and oxidative stress. Six GOs contained the term "homeostasis" and three GOs were related to cell apoptosis. There was no significantly enriched pathway using upregulated DEGs in PTC group. in HT-PTC group but no pathway was enriched in PTC group (Table 4) . Ten pathways were related to immune process, and only one pathway, the chemokine signaling pathway, was correlated with carcinogenesis. The enrichment plots from GSEA using our three ROS-related gene sets are shown in Fig. 6 . Gene Sets 1 and 3 were significantly enriched toward the HT-PTC group, using FDR q-value < 0.25. Gene Set 2 was also enriched toward HT-PTC side but had no significant q-value. This result suggests that the ROSrelated gene sets are highly activated in the HT-PTC group. 
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Discussion
Increased levels of ROS and oxidative stress are strongly associated with age-dependent disease, chronic inflammation, and increased risk of cancer development [23] . As discussed in a recent review article, many studies have
shown that the loss of ROS balance is related to cancer, such as cancer of the breast, prostate, liver, lung, pancreas and so on. Furthermore, known cancerrelated pathways, such as chemokine, c-myc, EGF, DNA repair mechanism, JAK/STAT, JNK, MAPK, mTOR, PI3K/Akt, p53, and PTEN, are linked with altered ROS status [24] . A recent clinical experimental study with radical prostatectomy tissue has shown that Nox-5 derived ROS exerts a carcinogenic effect by depletion of protein kinase C zeta and c-Jun N-terminal kinase (JNK) [25] .
In the same context, oxidative stress and elevated ROS levels have been proposed to be a risk factor for the development of thyroid cancer [26] [27] [28] .
Various experimental methods have been developed to detect the levels of ROS in specific tissues. However, these techniques tend to be extremely demanding for a variety of reasons. For instance, ROS have extremely short half-lives, generally on the order of nanoseconds to seconds. Moreover, their steady-state concentrations are in the picomolar to very low nanomolar range. ROS detection techniques also have demanding experimental requirements, such as fresh blood or tissue, expensive detection kits, and specialized techniques [29] . However, estimating the ROS level in thyroid or thyroid cancer tissue is more challenging than in other organs because thyroid cells themselves normally produce substantial amounts of hydrogen peroxide. To protect itself from the harmful effects of hydrogen peroxide production, the thyroid gland contains many anti-ROS defense mechanisms, such as antioxidants and free radicalscavengers [16] . This active ROS-production and elimination system in normal thyroid tissue makes it difficult to conduct ROS-related experimental study in thyroid cancer or HT.
Several groups have developed promising methods for accurately quantifying the levels of ROS in thyroid tissue. Although these methods were shown to effectively estimate ROS levels in the thyroid, a biological or genomic relationship has not been clearly demonstrated between ROS and PTC using these methods [29] . Only a limited number of genomic studies focusing on ROS-related genes in thyroid cancer or HT have been performed. Moreover, the genomic studies that have been performed have focused on specific genes, including DUOX1/2, NOX, TPO, TG, GSH and GPX [30] [31] [32] [33] [34] . In 2013, Martinez et al. performed a purely bioinformatics-based analysis of TCGA data and found that the oxidative response pathway is frequently down-regulated in PTC via genomic and epigenetic mechanisms [35] . However, only one protein complex, the KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex, was considered in the activation of the pathway. Furthermore, samples were not grouped according to their clinical information such as thyroiditis.
According to our TCGA RNA-sequencing data analysis, a number of ROSrelated genes were significantly up-regulated in the HT-PTC group. Compared with the PTC group, more genes were up-regulated in the HT-PTC group including those that showed higher fold changes. Among the up-regulated genes, NCF1, CYBB, SOD2 and NCF2 are dominantly expressed in immune cells and its role in the ROS system is correlated with ROS production. In contrast, genes that are dominantly expressed in thyroid tissue, TPO, IPCEF1, GPX3, SOD2, PRDX1, ETFDH, NDUFS1 and PRDX3, are correlated with ROS elimination (Table 1) . From this result, we can infer that ROS from immune cells are increased, and that the protective mechanism from thyroid cells was enhanced against the increased ROS from immune cells in the HT-PTC microenvironment.
In the validation study from microarray data, part of the ROS-related DEGs from TCGA had the same expression pattern between the two PTC groups.
Moreover, genes that showed higher fold change value over Our study proposed to obtain genomic evidence of ROS elevation in PTC with HT by RNA sequencing and microarray, without resorting to difficult ROS detection experiments. Increased ROS from immune cells in HT status can destroy the normal thyroid tissue by its cytotoxic effect which can then lead to thyroid cancer development. In the GSEA result in Table 3 , the HT-PTC group was more enriched than the PTC group in immune function-related pathways and one cancer related pathway, the "chemokine signaling pathway", that In summary, we obtained several lines of evidence that ROS levels are altered in HT-PTC using recent public next-generation sequencing and microarray data. First, more DEGs were observed in the HT-PTC group compared with the PTC group (33 versus 9), and the functions of the upregulated genes in the HT-PTC group were associated with ROS production in immune cell-related genes and ROS elimination in thyroid cell related genes.
Second, part of the ROS-related DEGs showed a similar expression pattern in HT in microarray data analysis. Third, the fold changes were higher in the HT-PTC group, as demonstrated by the difference in mean log fold change.
Thirteen genes in the HT-PTC group had log fold changes greater than 0.5, whereas only one gene in the PTC group exhibited this degree of change. Fourth, immune function-related pathways and one cancer-related pathway were significantly associated with HT-PTC group only. Finally, the ROS-related gene sets were enriched only in the HT-PTC group. Taken together, ROS levels may be elevated to sufficiently high levels that it contributes to the progression of carcinogenesis in HT-PTC. 
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